PriceTargets.com logo

Mirati Therapeutics - MRTX Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$58.70 As of 01/23/2024 01:00 AM ET
+0 (0.00%)
Get New Mirati Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MRTX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MRTX

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Mirati Therapeutics in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $58.70.

This chart shows the closing price for MRTX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 investment analysts is to n/a stock in Mirati Therapeutics. This rating changed within the last month from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 6 hold ratings
  • 0 sell ratings
Ratings as of
6/29/2023
  • 0 strong buy ratings
  • 7 buy ratings
  • 4 hold ratings
  • 1 sell ratings
Ratings as of
9/27/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 11 hold ratings
  • 0 sell ratings
Ratings as of
12/26/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 11 hold ratings
  • 0 sell ratings
Ratings as of
3/25/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 11 hold ratings
  • 0 sell ratings
Ratings as of
6/23/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 10 hold ratings
  • 0 sell ratings
Ratings as of
9/21/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/20/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/20/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/20/2023CitigroupReiterated RatingBuy ➝ Neutral$48.00 ➝ $59.00
11/7/2023Leerink PartnrsDowngradeOutperform ➝ Market Perform
11/7/2023Leerink PartnersReiterated RatingOutperform ➝ Market Perform$78.00 ➝ $58.00
11/7/2023Stifel NicolausReiterated RatingBuy ➝ Hold$83.00 ➝ $59.00
10/9/2023Piper SandlerDowngradeOverweight ➝ Neutral$58.00
10/9/2023B. RileyDowngradeBuy ➝ Neutral$65.00 ➝ $60.00
10/9/2023ScotiabankUpgradeUnderperform ➝ Sector Perform$58.00
10/9/2023Jefferies Financial GroupDowngradeBuy ➝ Hold$55.00 ➝ $58.00
10/9/2023JMP SecuritiesDowngradeOutperform ➝ Market Perform
10/6/2023Stifel NicolausReiterated RatingBuy ➝ Buy$83.00
10/6/2023BMO Capital MarketsBoost TargetMarket Perform ➝ Market Perform$31.00 ➝ $72.00
10/6/2023JMP SecuritiesBoost TargetMarket Outperform ➝ Market Outperform$58.00 ➝ $82.00
9/28/2023JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$58.00
8/10/2023CitigroupUpgradeNeutral ➝ Buy$51.00 ➝ $48.00
8/9/2023Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$42.00 ➝ $37.00
8/9/2023Piper SandlerInitiated CoverageOverweight$45.00
8/9/2023BMO Capital MarketsLower TargetMarket Perform ➝ Market Perform$40.00 ➝ $31.00
8/9/2023Stifel NicolausBoost Target$77.00 ➝ $83.00
8/9/2023B. RileyUpgradeNeutral ➝ Buy$45.00
8/9/2023OppenheimerBoost TargetOutperform ➝ Outperform$56.00 ➝ $62.00
7/27/2023ScotiabankInitiated CoverageUnderperform
7/24/2023GuggenheimLower TargetBuy$104.00 ➝ $60.00
7/24/2023B. RileyLower TargetNeutral$51.00 ➝ $45.00
7/24/2023Bank of AmericaLower Target$54.00 ➝ $46.00
7/24/2023BarclaysLower TargetOverweight$75.00 ➝ $71.00
7/14/2023Morgan StanleyLower TargetEqual Weight$51.00 ➝ $42.00
5/25/2023OppenheimerUpgradeMarket Perform ➝ Outperform
5/25/2023BMO Capital MarketsLower Target$50.00 ➝ $40.00
5/25/2023BarclaysLower Target$90.00 ➝ $75.00
5/11/2023VNET GroupReiterated RatingMaintains
5/11/202322nd Century GroupReiterated RatingReiterates
5/10/2023Stifel NicolausLower Target$78.00 ➝ $77.00
3/1/2023BMO Capital MarketsLower TargetMarket Perform$59.00 ➝ $50.00
1/27/2023Morgan StanleyLower TargetEqual Weight$60.00 ➝ $50.00
1/23/2023B. RileyBoost TargetNeutral$52.00 ➝ $56.00
12/14/2022Morgan StanleyLower TargetEqual Weight$70.00 ➝ $60.00
12/14/2022Leerink PartnersLower TargetOutperform$85.00 ➝ $75.00
12/14/2022Needham & Company LLCInitiated CoverageHold
12/14/2022BarclaysLower Target$169.00 ➝ $90.00
12/13/2022Piper SandlerBoost Target$84.00 ➝ $87.00
12/9/2022Stifel NicolausLower Target$73.00
12/9/2022CitigroupDowngradeBuy ➝ Neutral$121.00 ➝ $53.00
12/8/2022Leerink PartnersLower TargetOutperform$102.00 ➝ $85.00
12/8/2022Bank of AmericaLower Target$100.00 ➝ $61.00
12/8/2022BMO Capital MarketsDowngradeOutperform ➝ Market Perform$110.00 ➝ $59.00
12/8/2022Piper SandlerLower TargetOverweight$110.00 ➝ $84.00
12/8/2022JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$94.00 ➝ $65.00
12/8/2022OppenheimerLower TargetMarket Perform$85.00 ➝ $60.00
11/16/2022CitigroupLower TargetBuy$127.00 ➝ $121.00
11/9/2022Leerink PartnersLower TargetOutperform$111.00 ➝ $102.00
10/28/2022B. RileyInitiated CoverageNeutral$72.00
9/26/2022JPMorgan Chase & Co.Lower TargetOverweight$109.00 ➝ $94.00
9/15/2022Piper SandlerInitiated CoverageOverweight$110.00
9/13/2022JonestradingInitiated CoverageBuy$100.00
8/4/2022JMP SecuritiesBoost TargetMarket Outperform$72.00 ➝ $90.00
7/7/2022CitigroupLower TargetBuy$208.00 ➝ $127.00
6/9/2022OppenheimerLower Target$85.00
6/7/2022BMO Capital MarketsReiterated RatingBuy$80.00
6/7/2022The Goldman Sachs GroupLower TargetBuy$216.00 ➝ $188.00
6/7/2022Stifel NicolausBoost Target$105.00 ➝ $111.00
6/7/2022JMP SecuritiesUpgradeMarket Perform ➝ Outperform$72.00
6/4/2022JonestradingReiterated RatingBuy$100.00
5/27/2022Leerink PartnersLower TargetOutperform$164.00 ➝ $111.00
5/24/2022The Goldman Sachs GroupLower TargetBuy$253.00 ➝ $216.00
5/20/2022GuggenheimUpgradeNeutral ➝ Buy$115.00
5/5/2022CitigroupLower Target$227.00 ➝ $208.00
3/2/2022CitigroupLower TargetBuy$244.00 ➝ $227.00
3/1/2022Stifel NicolausLower TargetBuy$150.00 ➝ $118.00
3/1/2022Morgan StanleyLower TargetEqual Weight$150.00 ➝ $140.00
3/1/2022BMO Capital MarketsLower Target$187.00 ➝ $130.00
2/18/2022OppenheimerLower Target$175.00 ➝ $155.00
2/8/2022Leerink PartnersReiterated RatingOutperform
2/1/2022Morgan StanleyLower TargetEqual Weight$175.00 ➝ $150.00
2/1/2022Bank of AmericaUpgradeUnderperform ➝ Neutral$171.00 ➝ $141.00
11/18/2021BMO Capital MarketsInitiated CoverageOutperform$187.00
9/22/2021Stifel NicolausInitiated CoverageBuy$202.00
9/22/2021CitigroupBoost TargetBuy$232.00 ➝ $244.00
9/21/2021Morgan StanleyBoost TargetEqual Weight$160.00 ➝ $173.00
9/21/2021Leerink PartnersBoost TargetOutperform$195.00 ➝ $205.00
9/21/2021OppenheimerBoost TargetMarket Perform$160.00 ➝ $175.00
9/20/2021Jefferies Financial GroupInitiated CoverageBuy$193.00
9/19/2021Leerink PartnersReiterated RatingBuy
9/7/2021JPMorgan Chase & Co.Lower TargetOverweight$205.00 ➝ $203.00
8/26/2021Morgan StanleyInitiated CoverageEqual Weight$160.00
8/9/2021HC WainwrightLower TargetBuy$251.00 ➝ $247.00
6/4/2021CitigroupUpgradeNeutral ➝ Buy
5/24/2021OppenheimerReiterated RatingOutperform ➝ Market Perform$245.00 ➝ $160.00
5/17/2021OppenheimerDowngradeOutperform ➝ Market Perform$245.00 ➝ $160.00
5/10/2021HC WainwrightLower TargetBuy$255.00 ➝ $251.00
5/10/2021Jefferies Financial GroupUpgradeHold ➝ Buy$208.00 ➝ $196.00
3/1/2021OppenheimerLower TargetOutperform$260.00 ➝ $255.00
3/1/2021HC WainwrightLower TargetBuy$257.00 ➝ $255.00
1/15/2021HC WainwrightLower TargetBuy$265.00 ➝ $257.00
12/16/2020Credit Suisse GroupBoost TargetOutperform$225.00 ➝ $285.00
12/8/2020Evercore ISIInitiated CoverageOutperform
12/8/2020JMP SecuritiesInitiated CoverageMarket Perform
11/17/2020Bank of AmericaDowngradeNeutral ➝ Underperform$196.00
11/10/2020Jefferies Financial GroupDowngradeBuy ➝ Hold$206.00 ➝ $208.00
11/10/2020GuggenheimDowngradeBuy ➝ Neutral$230.00
11/9/2020HC WainwrightBoost TargetBuy$233.00 ➝ $265.00
11/5/2020OppenheimerBoost Target$225.00 ➝ $260.00
11/5/2020Piper SandlerBoost TargetOverweight$210.00 ➝ $260.00
11/2/2020HC WainwrightLower TargetBuy$238.00 ➝ $233.00
10/29/2020BarclaysBoost TargetOverweight$143.00 ➝ $244.00
10/27/2020Credit Suisse GroupBoost TargetOutperform$190.00 ➝ $225.00
10/26/2020OppenheimerBoost TargetOutperform$190.00 ➝ $225.00
10/26/2020Leerink PartnersBoost TargetOutperform$134.00 ➝ $195.00
10/26/2020The Goldman Sachs GroupBoost TargetBuy$152.00 ➝ $267.00
10/26/2020HC WainwrightBoost TargetBuy$222.00 ➝ $238.00
10/26/2020Piper SandlerBoost TargetOverweight$170.00 ➝ $210.00
10/21/2020BMO Capital MarketsBoost TargetMarket Perform$101.00 ➝ $176.00
10/16/2020HC WainwrightBoost TargetBuy$185.00 ➝ $222.00
10/8/2020CSFBBoost TargetOutperform$140.00 ➝ $190.00
10/8/2020Credit Suisse GroupBoost TargetOutperform$140.00 ➝ $190.00
9/28/2020Bank of AmericaInitiated CoverageNeutral$172.00
9/21/2020OppenheimerBoost TargetOutperform$133.00 ➝ $190.00
9/21/2020Piper SandlerBoost TargetOverweight$145.00 ➝ $170.00
9/18/2020CitigroupDowngradeBuy ➝ Neutral$127.00 ➝ $183.00
9/17/2020HC WainwrightBoost TargetBuy$163.00 ➝ $185.00
8/10/2020OppenheimerBoost Target$105.00 ➝ $133.00
8/10/2020HC WainwrightReiterated RatingBuy$163.00
8/7/2020Credit Suisse GroupBoost TargetOutperform$135.00 ➝ $140.00
8/7/2020BarclaysBoost TargetOverweight$123.00 ➝ $143.00
7/29/2020Credit Suisse GroupBoost TargetOutperform$115.00 ➝ $135.00
5/1/2020JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$116.00
4/16/2020The Goldman Sachs GroupInitiated CoverageBuy$151.00
3/30/2020OppenheimerLower TargetOutperform$129.00 ➝ $105.00
3/12/2020JPMorgan Chase & Co.UpgradeUnderweight ➝ Neutral$88.00
2/28/2020HC WainwrightReiterated RatingBuy$134.00 ➝ $126.00
1/27/2020BMO Capital MarketsInitiated CoverageMarket Perform$101.00
1/24/2020HC WainwrightReiterated RatingBuy$117.00 ➝ $134.00
1/7/2020CowenReiterated RatingBuy
(Data available from 12/21/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/25/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/23/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/21/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Mirati Therapeutics logo
Mirati Therapeutics, Inc., a commercial-stage oncology company, develops novel therapeutics to address the genetic and immunological promoters of cancer in the United States. The company provides KRAZATI, an oral targeted treatment option for adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung (NSCLC), as well as in clinical development as a monotherapy and in combination with other agents. It also develops Sitravatinib, an investigational spectrum-selective kinase inhibitor in Phase 3 clinical development that inhibits receptor tyrosine kinases (RTKs), including TAM family receptors, split family receptors, and RET, which overcomes resistance to checkpoint inhibitor therapy through targeted reversal of an immunosuppressive tumor microenvironment that enhances antigen-specific T cell response and expanding dendritic cell-dependent antigen presentation. In addition, the company pipeline comprises the MRTX1719, an investigational synthetic lethal PRMT5 inhibitor designed to target the PRMT5/methylthioadensoine (MTA) complex and is in clinical development; MRTX0902, a selective SOS1 inhibitor that improves anti-tumor efficacy in combination with targeted mitogen-activated protein kinase (MAPK)-pathway inhibitors, and is in clinical development; and MRTX1133, an investigational lead KRAS G12D compound. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib; and Zai Lab Ltd. to research, develop, manufacture, and commercialize adagrasib in various indications. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $58.70
Low: $58.70
High: $58.70

50 Day Range

MA: $58.82
Low: $58.70
High: $59.28

52 Week Range

Now: $58.70
Low: $27.30
High: $64.41

Volume

N/A

Average Volume

2,758,857 shs

Market Capitalization

$4.12 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.77

Frequently Asked Questions

What sell-side analysts currently cover shares of Mirati Therapeutics?

The following Wall Street analysts have issued research reports on Mirati Therapeutics in the last twelve months: StockNews.com.
View the latest analyst ratings for MRTX.

What is the current price target for Mirati Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Mirati Therapeutics in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Mirati Therapeutics in the next year.
View the latest price targets for MRTX.

What is the current consensus analyst rating for Mirati Therapeutics?

Mirati Therapeutics currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for MRTX.

What other companies compete with Mirati Therapeutics?

Other companies that are similar to Mirati Therapeutics include Viatris, Royalty Pharma, Summit Therapeutics, Genmab A/S and Insmed. Learn More about companies similar to Mirati Therapeutics.

How do I contact Mirati Therapeutics' investor relations team?

Mirati Therapeutics' physical mailing address is 9393 TOWNE CENTRE DRIVE SUITE 200, SAN DIEGO CA, 92121. The biotechnology company's listed phone number is (858) 332-3410 and its investor relations email address is [email protected]. The official website for Mirati Therapeutics is www.mirati.com. Learn More about contacing Mirati Therapeutics investor relations.